logo-loader

Verona Pharma

Receive alerts
Market:
AIM
Market Cap:
£43.71 m
Price
41.50 GBX
Change
0.00%
52 weeks high
106.20
52 weeks low
39.60

In brief

Verona Pharma plc is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD, cystic fibrosis and asthma. The Company is listed on the Nasdaq Global Market in the United States under the VRNA ticker and on the London Stock Exchange in the United Kingdom under the VRP.L ticker. Read more here about Verona Pharma's science and innovative therapeutics.

Deep dive We explore the investor case for growth companies

Snapshot

A phase IIb study is currently underway for the nebulised version of ensifentrine with the read-out expected “around the end of the year”